Uncategorized
Icon Bioscience Annouces FDA Acceptance of NDA Filing for DEXYCU, a Noval Drug Therapy for Treating Inflammation Associated with Cataract Surgery
NEWARK, Calif.--(BUSINESS WIRE)--Icon Bioscience gets PDUFA date for its NDA filing of DEXYCU, a dropless treatment for inflammation associated with cataract surgery